Bragar Eagel & Squire, P.C. Announces that it Is Investigating the Boards of Directors of Home BancShares, Valley National, Kraton Corporation, and Acceleron Pharma on behalf of Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. announces to investors that it is investigating potential claims on behalf of stockholders of Home BancShares, Inc. (NASDAQ: HOMB), Valley National Bancorp (NASDAQ: VLY), Kraton Corporation (NYSE: KRA), and Acceleron Pharma, Inc. (NASDAQ: XLRN).  Additional information about each potential action can be found at the link provided.

Home Bancshares, Inc. (NASDAQ: HOMB)

On September 28, 2021, Home BancShares announced that it had entered into an agreement to acquire Happy Bancshares in a transaction valued at approximately $919 million. Pursuant to the merger agreement, Happy Bancshares stockholders will receive 2.17 shares of Home BancShares common stock for each share of Happy Bancshares common stock owned. The deal is scheduled to close in the first quarter of 2022.

Bragar Eagel & Squire is concerned that Home BancShares' board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Home BancShares' stockholders.

To learn more about the Home BancShares investigation go to: https://bespc.com/cases/homb .

Valley National Bancorp (NASDAQ: VLY)

On September 23, 2021, Valley National announced that it had entered into an agreement to acquire Leumi in a stock-plus-cash transaction. Pursuant to the merger agreement, Leumi stockholders will receive $5.08 in cash and 3.8025 shares of Valley National common stock for each share of Leumi common stock owned. The deal is scheduled to close in the first quarter of 2022.

Bragar Eagel & Squire is concerned that Valley National's board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Valley National's stockholders.

To learn more about the Valley National investigation go to: https://bespc.com/cases/vly .

Kraton Corporation (NYSE: KRA)

Buyer: DL Chemical Co., Ltd.

On September 27, 2021, Kraton announced that it had entered into an agreement to be acquired by DL Chemical in a transaction valued at approximately $2.5 billion. Pursuant to the merger agreement, Kraton stockholders will receive $46.50 in cash for each share of Kraton common stock owned. The deal is scheduled to close in the first half of 2022.

Bragar Eagel & Squire is concerned that Kraton's board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Kraton's stockholders.

To learn more about the Kraton investigation go to: https://bespc.com/cases/kra .

Acceleron Pharma, Inc. (NASDAQ: XLRN)

Buyer: Merck & Co., Inc. (NYSE: MRK)

On September 30, 2021, Acceleron announced that it had entered into an agreement to be acquired by Merck in a transaction valued at approximately $11.5 billion. Pursuant to the merger agreement, Acceleron stockholders will receive $180 in cash for each share of Acceleron common stock owned. The deal is scheduled to close in the fourth quarter of 2021.

Bragar Eagel & Squire is concerned that Acceleron's board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Acceleron's stockholders.

To learn more about the Acceleron investigation go to: https://bespc.com/cases/xlrn .

About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com . Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information:
Bragar Eagel & Squire, P.C.
Melissa A. Fortunato, Esq.
Alexandra Raymond, Esq.
investigations@bespc.com
www.bespc.com


News Provided by GlobeNewswire via QuoteMedia

The Conversation (0)
Medicine capsule showing active ingredients.

5 Biggest Pharma Stocks in 2025

The pharmaceutical industry is a major player in the overall life science sector, responsible for developing and manufacturing the majority of prescription drugs. Companies in this space are constantly researching and creating innovative treatments for various medical conditions. In recent... Keep Reading...
Seegnal Inc. (TSXV:SEGN)

Seegnal Inc. Announces Extension of Maccabi Health Services Contract

Seegnal Inc. (TSXV: SEGN) ("Seegnal" or the "Corporation"), a global leader in SaaS clinical division support solutions, is pleased to announce that effective September 8, 2025, it has amended its contract with Maccabi Health Services ("Maccabi") for an additional six years and has also expanded... Keep Reading...
Numinus Wellness Inc. Announces Third Quarter Fiscal 2025 Results

Numinus Wellness Inc. Announces Third Quarter Fiscal 2025 Results

All financial results are reported in Canadian dollars unless otherwise stated. Numinus Wellness Inc. (TSX: NUMI) (OTCQB: NUMIF) (FSE: LR23) ("Numinus" or the "Company") a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based... Keep Reading...
Invion Executive Chair and CEO Thian Chew.

Invion CEO Maps Path to Peer-level Valuation as Momentum for Cancer Treatment Trials Builds

Invion (ASX:IVX) Executive Chair and CEO Thian Chew says the company sees a path to a rerate toward clinical-stage oncology peers — typically valued from AU$30 million to AU$40 million up to several hundred million — if it executes on a trio of near-term priorities: simplifying licencing,... Keep Reading...
Numinus Wellness Inc. Announces Second Quarter Fiscal 2025 Results

Numinus Wellness Inc. Announces Second Quarter Fiscal 2025 Results

All financial results are reported in Canadian dollars unless otherwise stated. Numinus Wellness Inc. (TSX: NUMI) (OTCQB: NUMIF) (FSE: LR23) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based... Keep Reading...

Latest Press Releases

Related News